LEXT

Lexston Life Sciences CNSX:LEXT Stock Report

Last Price

CA$0.065

Market Cap

CA$763.5k

7D

30.0%

1Y

-91.3%

Updated

03 Jul, 2022

Data

Company Financials
LEXT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

LEXT Stock Overview

Lexston Life Sciences Corp. provides contract-based research services for the detection and screening of pathogens, analytical testing services for mid-stream cannabinoid potency, and stability testing services.

Lexston Life Sciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lexston Life Sciences
Historical stock prices
Current Share PriceCA$0.065
52 Week HighCA$1.40
52 Week LowCA$0.05
Beta0
1 Month Change18.18%
3 Month Change-62.86%
1 Year Change-91.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.67%

Recent News & Updates

Shareholder Returns

LEXTCA Life SciencesCA Market
7D30.0%-5.9%-0.8%
1Y-91.3%-17.5%-5.0%

Return vs Industry: LEXT underperformed the Canadian Life Sciences industry which returned -17.5% over the past year.

Return vs Market: LEXT underperformed the Canadian Market which returned -5% over the past year.

Price Volatility

Is LEXT's price volatile compared to industry and market?
LEXT volatility
LEXT Average Weekly Movement44.7%
Life Sciences Industry Average Movement11.4%
Market Average Movement10.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market4.4%

Stable Share Price: LEXT is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 45% a week.

Volatility Over Time: LEXT's weekly volatility has increased from 27% to 45% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aJag Balhttps://lexston.ca

Lexston Life Sciences Corp. provides contract-based research services for the detection and screening of pathogens, analytical testing services for mid-stream cannabinoid potency, and stability testing services. The company is headquartered in Vancouver, Canada.

Lexston Life Sciences Fundamentals Summary

How do Lexston Life Sciences's earnings and revenue compare to its market cap?
LEXT fundamental statistics
Market CapCA$763.54k
Earnings (TTM)CA$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LEXT income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$0
EarningsCA$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did LEXT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LEXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LEXT?

Other financial metrics that can be useful for relative valuation.

LEXT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does LEXT's PB Ratio compare to its peers?

LEXT PB Ratio vs Peers
The above table shows the PB ratio for LEXT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.1x
IOT Innovotech
5.6xn/aCA$6.4m
TELI Telescope Innovations
4.6xn/aCA$12.2m
DOSE Rapid Dose Therapeutics
5.7xn/aCA$20.0m
WLNS Discover Wellness Solutions
0.3xn/aCA$798.3k
LEXT Lexston Life Sciences
n/an/aCA$763.5k

Price-To-Book vs Peers: Insufficient data to calculate LEXT's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does LEXT's PE Ratio compare vs other companies in the North American Life Sciences Industry?

Price-To-Book vs Industry: Insufficient data to calculate LEXT's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is LEXT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LEXT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LEXT's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LEXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LEXT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LEXT's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LEXT's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at our analysis of LEXT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Lexston Life Sciences regulatory filings.

Future Growth

How is Lexston Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lexston Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of LEXT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Lexston Life Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Lexston Life Sciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


32.6%

Historical Pharmaceuticals & Biotech annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Lexston Life Sciences has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Discover strong past performing companies

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Lexston Life Sciences's management and board experience and expertise to assess their ability to deliver on their strategic promises.

Financial Health

How is Lexston Life Sciences's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Lexston Life Sciences's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Lexston Life Sciences has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Discover healthy companies

  • Take a look at our analysis of LEXT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Lexston Life Sciences's cash and debt levels may be found in its annual reports archived here.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Lexston Life Sciences's financial data was last updated here.

Dividend

What is Lexston Life Sciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LEXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LEXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LEXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LEXT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LEXT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jag Bal (50 yo)

no data

Tenure

Mr. Jagdip Bal, also known as Jag, was the Chief Executive Officer and President of Heritage Cannabis Holdings Corporation (formerly Umbral Energy Corp., and prior to that was named Trijet Mining Corp.), s...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LEXT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.5%.


Top Shareholders

Company Information

Lexston Life Sciences Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lexston Life Sciences Corp.
  • Ticker: LEXT
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$763.537k
  • Shares outstanding: 11.75m
  • Website: https://lexston.ca

Location

  • Lexston Life Sciences Corp.
  • 929 Mainland Street
  • Vancouver
  • British Columbia
  • V6B 1S3
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/06/29 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.